Drug intelligence / Profile preview

WPC07

Development stage: Preclinical
Lead developer: Westlake Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

WPC07 is a small molecule therapeutic candidate developed by Westlake Pharmaceuticals (Westlake Therapeutics) for the treatment of cancer. Currently in the drug discovery stage, WPC07 is designed to target epigenetic regulators and transcription factors. By modulating these key drivers of gene expression, the drug aims to disrupt oncogenic signaling pathways and inhibit tumor growth. It represents part of Westlake's pipeline focused on innovative small molecule inhibitors for oncology indications.

Targets

TF (Transferrin)

Beyond the preview

Go deeper on WPC07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPC07.

Explore the full profile